Australia Health News API

{
    "totalArticles": 190688,
    "articles": [
        {
            "id": "1437e0d4a00adaca30995df42927b0c6",
            "title": "Special Needs Plans' Impact on Dementia Care Outcomes",
            "description": "About The Study: In this retrospective cohort study, Institutional Special Needs Plan (I-SNP) enrollment was associated with significantly fewer",
            "content": "Why?\nWell, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don't put up a paywall – we believe in free access to information of public interest.\nMedia ownership in Australia is one of the most concentrat... [1010 chars]",
            "url": "https://www.miragenews.com/special-needs-plans-impact-on-dementia-care-1683486/",
            "image": "https://cdn1.miragenews.com/tmp_cache?cdn=images.unsplash.com%2Fphoto-1581595220921-eec2071e5159%3Fixlib%3Drb-4.0.3%26amp%3Bixid%3DMnwxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8%26amp%3Bauto%3Dformat%26amp%3Bfit%3Dcrop%26amp%3Bw%3D1170%26amp%3Bq%3D80",
            "publishedAt": "2026-05-31T15:08:00Z",
            "lang": "en",
            "source": {
                "id": "0368281c39ba31f7435685e8b620f675",
                "name": "Mirage News",
                "url": "https://www.miragenews.com"
            }
        },
        {
            "id": "730df3865e2104c892f770bc3bec197b",
            "title": "Dresden Reveals Promising Therapy for Solid Tumors",
            "description": "As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in",
            "content": "As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a so-called bispecific T-cell engager (TCER) that specifi... [4326 chars]",
            "url": "https://www.miragenews.com/dresden-reveals-promising-therapy-for-solid-1683478/",
            "image": "https://cdn1.miragenews.com/tmp_cache?cdn=images.unsplash.com%2Fphoto-1584515933487-779824d29309%3Fixlib%3Drb-4.0.3%26amp%3Bixid%3DMnwxMjA3fDB8MHxwaG90by1wYWdlfHx8fGVufDB8fHx8%26amp%3Bauto%3Dformat%26amp%3Bfit%3Dcrop%26amp%3Bw%3D1170%26amp%3Bq%3D80",
            "publishedAt": "2026-05-31T14:24:00Z",
            "lang": "en",
            "source": {
                "id": "0368281c39ba31f7435685e8b620f675",
                "name": "Mirage News",
                "url": "https://www.miragenews.com"
            }
        },
        {
            "id": "98133f9e2e27813d3bf2f2b5b3c0b5cc",
            "title": "GLP-1 therapies key to Australia’s new obesity and CVD…",
            "description": "The National Heart Foundation released a practical guide for treating obesity and cardiovascular disease, and GLP-1 therapies are key.",
            "content": "The National Heart Foundation of Australia presented Australia’s first clinical consensus statement on obesity and cardiovascular disease (CVD) at the WHO World Health Assembly in Geneva.\nThe statement is the first to provide clear advice for the use... [6484 chars]",
            "url": "https://insightplus.mja.com.au/2026/21/glp-1-therapies-key-to-australias-new-obesity-and-cvd-treatment-guide",
            "image": "https://cdn.craft.cloud/019da4e9-f79c-70fd-9f88-624918b9686f/assets/thumbnail/lead-image-2026-05-28T132430.430.png?fit=cover&height=630&width=1200&s=Yp9PE4ljhCXUF0Z6W2cXcLkuVRx0MNE6ZiDdRe0uD0Y",
            "publishedAt": "2026-05-31T14:06:21Z",
            "lang": "en",
            "source": {
                "id": "74b3be1e44ce1f9603e4ee104bd718d7",
                "name": "The Medical Journal of Australia",
                "url": "https://insightplus.mja.com.au"
            }
        }
    ]
}